Influence of atorvastatin on C-reactive protein level and clinical prognosis for chronic cardiac insufficiency combined with paroxysmal atrial fibrillation patients
10.3760/cma.j.issn.1673-4904.2012.28.008
- VernacularTitle:阿托伐他汀对慢性心功能不全合并阵发性心房颤动患者C反应蛋白水平及临床预后的影响
- Author:
Zongmei DUAN
- Publication Type:Journal Article
- Keywords:
Atrial fibrillation;
C-reactive protein;
Atorvastatin
- From:
Chinese Journal of Postgraduates of Medicine
2012;35(28):21-23
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo investigate the influence of atorvastatin on C-reactive protein (CRP) level and clinical prognosis for chronic cardiac insufficiency combined with paroxysmal atrial fibrillation patients.Methods One hundred and eight-six chronic cardiac insufficiency combined with paroxysmal atrial fibrillation patients were divided into observation group(93 cases) and control group (93 cases) by random number table.The control group was given conventional treatment such as cardiotonic and diuretic,while the observation group was given atorvastatin 20 mg one time/night for 1 year on the basis of conventional treatment.Before and after treatment,lipid,left atrial diameter,left ventricular ejection fraction (LVEF),CRP and clinical outcome were compared.Results Lipid levels of the control group were not significantly different before and after treatment(P ＞ 0.05 ).In observation group,the levels of total cholesterol (TC),low density lipoprotein-cholesterol (LDL-C) and highdensity lipoprotein-cholesterol(HDL-C) after treatment were improved compared with those before treatment [ (4.1 ± 0.6) mmol/L vs.(4.8 ± 0.6) mmol/L,(2.7 ±0.3) mmol/L vs. (3.5 ±0.5) mmol/L,(1.0 ±0.1) mmol/L vs. (0.9 ±0.1) mmol/L,P ＜0.05].After treatment,the levels of TC,LDL-C and HDL-C in observation group were improved compared with those in control group (P＜ 0.05 ).There was no significant difference in left atrial diameter and LVEF before and after treatment in two groups.The levels of CRP before and 1 month and 6 months after treatment were ( 15.2 ±3.8),(12.1 ±2.7),(9.9 ±2.8) mg/L in observation group,and (15.0 ±3.8),(14.0 ±2.9),(13.7 ±2.8)mg/L in control group,and there were significant differences between two groups 1 month and 6 months after treatment(P ＜ 0.05).The incidences of atrial fibrillation recurrence and conversion for persistent or permanent atrial fibrillation in observation group were significantly lower than those in control group [6.5％ (6/93) vs.21.5％ (20/93),6.5％ (6/93) vs.19.4％ ( 18/93 ),P ＜ 0.05 ].ConclusionAtorvastatin can reduce CRP level of chronic cardiac insufficiency combined with paroxysmal atrial fibrillation patients,and reduce and delay recurrence and progress of paroxysmal atrial fibrillation.
